• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Colony Stimulating Factor
    4 Drugs classified under this drug class

    All the Drug Class Drugs

    partial basket chart

    Colony Stimulating Factor. Lipegfilgrastim 6 mg / 0.6 ml.
    PREFILLED SYRINGE (sol. for inj.): 1 × 0.6
    ml. One 6 mg dose of (a single pref.
    syr.) for each chemoth. cycle, given approx. 24 hrs. after cytotoxic
    Reduct. in the durat. of neutropenia and
    the incidence of febrile neutropenia in
    adult pts. treated with cytotoxic
    chemother. for malignan. (with the
    except. of chron. myeloid leukaemia and
    myelodysplast. syndr.)
    C/I: Hypersens.

    partial basket chart

    Colony Stimulating Factor. Pegfilgrastim 6 mg / 0.6 ml.
    PREFILL SYRINGE (ready-to-use) 1 x 6
    mg/0.06 ml. One 6 mg dose for ea.
    chemother. cycle S.C. inject. approx.
    24 hrs follow. cytotox. chemother.
    Reduct. durat. neutropen., incidence of
    febrile neutropen. in pts. treated with cytotox. chemother. for malignancy (with
    the except. of chron. myeloid leukem. and
    myelodysplast. synds.)
    C/I: Hyperens.

    Neupogen 30 MU vials & 30 MU, 48 MU Pre-filled Syringe
    partial basket chart
    Neupogen 30 MU vials & 30 MU, 48 MU Pre-filled Syringe

    Colony Stimulating Factor. Filgrastim 30 MU/ml (0.3 mg/ml), 30 MU/0.5 ml (0.6 mg/ml), 48 MU/0.5 ml (0.96 mg/ml).
    VIALS (sol. for inj.): 5×30MU (0.3 mg/
    PREF. SYR. (sol. for inj.): 5×30MU (0.6 mg/
    ml), 1, 5×48MU (0.96 mg/ml). Dosage ajust. individ. accord. pt. med. condition.
    Reduct. in the duration of neutropenia and
    the incidence of febrile neutropenia in pts.
    treated with established cytotoxic
    chemother. for malign. (with the exception
    of chronic myeloid leukaemia and
    myelodysplastic syndr.) and for the reduct.
    in the duration of neutropenia in pts.
    undergoing myeloablative ther. followed
    by bone marrow transplant., considered
    to be at incr. risk of prolon. severe
    neutropenia. The safety and efficacy of
    Filgrastim are similar in adults and child.
    receiving cytotoxic chemother. Indic. for
    the mobilisation of peripheral blood
    progenitor cells (PBPCs). In pts., children/
    adults, with severe congen., cyclic or
    idiopathic neutropenia with an ANC of
    ≤0.5 ×10^9/l, and a history of severe or
    recurrent infec., long-term admin. of this
    drug is indicated to increase neutrophil
    counts and to reduce the incidence and
    duration of infect.-related events.
    C/I: Hypersens. Filgrastim should not be
    diluted with saline sol. Diluted filgrastim
    may be adsorbed to glass and plast.

    partial basket chart

    Colony Stimulating Factor. Filgrastim 0.6 mg/ml.
    PREFILLED SYRINGE: 1, 5, 10 x 30
    MIU/0.5 ml, 48 MIU/0.8 ml.
    0.5 MIU (5 μg)-1.2 MIU (12μg)/kg dly.
    See lit.
    Reduct. durat. neutropen., febrile
    neutropen. in pts. treated with establish.
    cytotoxic chemother. for malign. (except
    chron. myeloid leukem., myelodysplast.
    syndr.); reduct. durat. neutropen. in
    myeloablat. ther. foll. by bone marrow
    transplant. at incr. risk of prolong. Severe
    neutropen. For mobilisat. periph. Blood
    progenitor cells in normal donors. Long
    term admin. to incr. neutrophil counts
    and reduce incidence and durat. of
    infect.-relat. events in pts. with severe congen., cyclic, or idiopath. neutropen. with absolute neutrophil count (ANC) of 0.5 x 10^9/l and history of severe or recurr. infects. Tmt. persist. neutropen, (ANC < 1.0 x 10^9/l) in advanced HIV infect., to reduce risk of bact. infect. when other options inapprop.
    C/I: Known hypersens.